INTERFERON BETA-1A AND GLATLRAMER ACETATE TO EITHER AGENT ALONE IN PATIENTS W/MS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项由NIH资助的多中心研究，并得到了两个商业来源的额外支持。该III期研究的既定目标是“确定干扰素β 1-a（Avonex）和醋酸格拉替雷（Copaxone）的组合是否是复发缓解型多发性硬化症的有效疗法”。 总共有20名患者（来自86家中心的1000名患者）将在GCRC就诊。这是一项大规模的随机临床试验，比较了两种常见干预措施的组合与每种单独治疗的效果（即，无安慰剂）。将比较疗效的结局是复发率，相对于任一单独治疗，联合治疗的预期效应量为复发率的35%。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center NIH-funded study with additional support from two commercial sources. The stated goal of this phase III study is "to determine whether the combination of interferon beta 1-a (Avonex) and glatiramer acetate (Copaxone) is an effective therapy for relapsing-remitting Multiple Sclerosis". A total of 20 patients (from the total of 1000 sought at 86 centers) will be seen at the GCRC. This is a large scale randomized clinical trial comparing the effects of a combination of two common interventions to each treatment alone (i.e., no placebo). The outcome on which efficacy will be compared is the relapse rate, the anticipated effect size of the combination is 35% in the relapse rate relative to either therapy alone.